These results suggest that c-Met and EPHA7 might be useful prognostic biomarkers, and the presumed myoferlin/c-Met pathway could be a novel therapeutic target in ccRCC. This evidence concerns the gene EPHA7 and nonpapillary renal cell carcinoma.